LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies

CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases

NCT06787560 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

NCT04599556 ·Status: RECRUITING ·Phase: PHASE1

CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

NCT04609241 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1

Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

NCT05239676 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases

NCT05827835 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

NCT03564977 ·Status: UNKNOWN ·Phase: NA

Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma

NCT04689659 ·Status: COMPLETED ·Phase: PHASE2

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

NCT04532268 ·Status: RECRUITING ·Phase: EARLY_PHASE1

NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

NCT04658004 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

NCT04603872 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

NCT04788472 ·Status: COMPLETED ·Phase: PHASE2

CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation

NCT07117305 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

NCT06633341 ·Status: RECRUITING ·Phase: EARLY_PHASE1

A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application

NCT02980315 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

NCT03796390 ·Status: UNKNOWN ·Phase: PHASE1

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

NCT04532281 ·Status: RECRUITING ·Phase: EARLY_PHASE1

CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

NCT03121625 ·Status: UNKNOWN ·Phase: PHASE1

Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia

NCT06585345 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

NCT04657861 ·Status: RECRUITING ·Phase: EARLY_PHASE1

IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia

NCT04599543 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1

CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases

NCT06279923 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL

NCT06633354 ·Status: RECRUITING ·Phase: EARLY_PHASE1

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

NCT05712083 ·Status: UNKNOWN ·Phase: PHASE2

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

NCT06346912 ·Status: RECRUITING ·Phase: EARLY_PHASE1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.

NCT06733610 ·Status: RECRUITING ·Phase: PHASE1